Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Dexamethasone 12Gemcitabine 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Docetaxel 9venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7Methotrexate 6130-nm albumin-bound paclitaxel 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × cedazuridine × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡